Bellus Health Inc

BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BELLUS Health is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. The lead program KIACTA™, a novel drug candidate, is in data review after announcing on June 20, 2016 top-line results from its Phase 3 study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTA™. KIACTA™ is also being developed as a treatment in a second indication called sarcoidosis, a rare, potentially fatal inflammatory condition that affects the lungs. An investigational new drug application (IND) for a Phase 2/3 clinical study is expected to be filed with the U.S. Food and Drug Administration in 2016. In addition, BELLUS Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS). sHUS often leads to dialysis, chronic kidney disease and in some cases death, particularly in children. Shigamab™ pre-clinical studies for the treatment of sHUS are currently underway.  BELLUS Health’s pipeline also includes a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body.

Investors need to pay close attention to BELLUS Health (BLU) stock based on the movements in the options market lately.

Implied Volatility Surging for BELLUS Health (BLU) Stock Options

BELLUS Health Inc (NASDAQ: BLU) is trading higher Monday after the company announced interim analysis from the Phase 2b SOOTHE trial of BLU-5937 in refractory chronic cough. The stock is experiencing high volatility, trading as high as $4.78 and as low as $3.63 in today's session.

What's Going On With BELLUS Health's Stock Today?

BELLUS Health Inc (NASDAQ: BLU) has announced a positive interim analysis from Phase 2b SOOTHE trial of BLU-5937 for refractory chronic cough (RCC). BLU-5937, the Company's lead program, is a highly selective P2X3 antagonist.

BELLUS Health Stock Shines After Refractory Chronic Cough Trial Data

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced positive findings from a preplanned administrative interim analysis of the ongoing Phase 2b SOOTHE trial of BLU-5937, the Company's highly selective P2X3 antagonist, in patients with refractory chronic cough

BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough

CTI BioPharma

ObsEva

Pieris Pharma

These penny stocks could be in focus as we turn the page on a new month. The post 5 Penny Stocks To Watch For September With Upcoming Events appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Watch For September With Upcoming Events

Bellus' lead drug candidate, BLU-5937, has the potential to capture significant market share if the drug attains commercialization. Bellus has adequate cash on its books, lasting until at least the duration of 2022. The company has no long-term debt.

Bellus Health - Betting Big On Chronic Cough Treatment

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that an abstract covering additional data from the RELIEF Phase 2a trial has been accepted for oral presentation at the upcoming European Respiratory Society (“ERS”) International Congress 2021, bein

BELLUS Health to Report Additional RELIEF Data in an Oral Presentation at the European Respiratory Society International Congress 2021

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the second quarter ending June 30, 2021. “Our focus remains on the completion of our two ongoing Phase 2 clinical trials – SOOTHE and BLUEPRINT – evaluating our selecti

BELLUS Health Reports Second Quarter 2021 Financial Results and Business Highlights

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will be participating in a fireside chat at the Jefferies Virtual Healthcare Conference. Presentation Details: Event: Jeff

BELLUS Health to Participate in the Jefferies Virtual Healthcare Conference

Los Angeles, California--(Newsfile Corp. - May 17, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BELLUS Health Inc. ("BELLUS" or "the Company") (NASDAQ: BLU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 5, 2019 and July 5, 2020, inclusive...

DEADLINE TODAY: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against BELLUS Health Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - May 17, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BELLUS Health Inc. (NASDAQ: BLU) between September 5, 2019 and July 5, 2020, inclusive (the "Class Period"), of the important May 17, 2021 lead plaintiff deadline.SO WHAT: If you purchased BELLUS securities during the Class Period you may be entitled to compensation without payment of any out of pocket...

BLU Final Deadline Today: Rosen, Trusted Investor Counsel, Encourages BELLUS Health Inc. Investors to Secure Counsel Before Important May 17 Deadline in Securities Class Action - BLU

New York, New York--(Newsfile Corp. - May 16, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of BELLUS Health Inc. ("BELLUS Health") (NASDAQ: BLU) between September 5, 2019 and July 5, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of BELLUS Health Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 17, 2021 - BLU

TORONTO--(BUSINESS WIRE)--Morganti & Co., A pro-investor law firm with licensed and experienced lawyers in Canada and the United States that represent investors announces the filing of a securities class action on behalf of investors who purchased or otherwise acquired common stock of Bellus Health, Inc. ("Bellus" or "Company") (NASDAQ: BLU, TSX: BLU, FWB: BHN0) from September 5, 2019 through July 5, 2020, inclusive (the "Class Period"). Bellus is a biopharmaceutical company whose lead prod

Morganti & Co., P.L.C. Announces the Filing of a Securities Class Action on Behalf of Investors Who Acquired Bellus Health, Inc.

New York, New York--(Newsfile Corp. - May 14, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased BELLUS Health Inc. ("BELLUS Health") (NASDAQ: BLU) between September 5, 2019 and July 5, 2020.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/bellus-health-inc-investigation-loss-submission-form?prid=15900&wire=5

BLU LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving BELLUS Health Inc.

New York, New York--(Newsfile Corp. - May 14, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BELLUS Health Inc. (NASDAQ: BLU) alleging that the Company violated federal securities laws.Class Period: September 5, 2019 and July 5, 2020Lead Plaintiff Deadline: May 17, 2021Learn more about your recoverable losses in BLU:

BLU ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 17, 2021 in the Class Action Filed on Behalf of BELLUS Health Inc. Limited Shareholders

New York, New York--(Newsfile Corp. - May 14, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BELLUS Health Inc. (NASDAQ: BLU) between September 5, 2019 and July 5, 2020, inclusive (the "Class Period"), of the important May 17, 2021 lead plaintiff deadline.SO WHAT: If you purchased BELLUS securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...

BLU FINAL DEADLINE: ROSEN, A TOP RANKED FIRM, Encourages BELLUS Health Inc. Investors to Secure Counsel Before Important Monday Deadline in Securities Class Action - BLU

Los Angeles, California--(Newsfile Corp. - May 14, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BELLUS Health Inc. ("BELLUS" or "the Company") (NASDAQ: BLU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 5, 2019 and July 5, 2020, inclusive...

DEADLINE MONDAY ALERT: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against BELLUS Health Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $BLU #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BELLUS Health Inc. (BLU)

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BELLUS Health Inc. (BLU)

Los Angeles, California--(Newsfile Corp. - May 13, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BELLUS Health Inc. ("BELLUS" or "the Company") (NASDAQ: BLU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 5, 2019 and July 5, 2020, inclusive...

MONDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against BELLUS Health Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK, May 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BELLUS Health Inc. ("BELLUS" or the "Company") (NASDAQ: BLU). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BELLUS Health Inc. - BLU

NEW YORK, May 12, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of BELLUS Health Inc. ("BELLUS " or the "Company") (NASDAQ: BLU) from September 5, 2019, through  July 5, 2020 (the "Class Period"). The lawsuit filed in the United States District Court for the Southern District of New York alleges violations of the Securities Exchange Act of 1934.

BLU INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff in a Securities Class Action Lawsuit Against BELLUS Health, Inc.

Los Angeles, California--(Newsfile Corp. - May 12, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BELLUS Health Inc. ("BELLUS" or "the Company") (NASDAQ: BLU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 5, 2019 and July 5, 2020, inclusive...

MONDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against BELLUS Health Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - May 12, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BELLUS Health Inc. ("BELLUS" or "the Company") (NASDAQ: BLU) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired BELLUS securities between September 5, 2019 and July 5, 2020, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's...

Deadline of May 17, 2021 for BELLUS Health Inc. (BLU) Class Action - Bronstein, Gewirtz & Grossman, LLC Encourages Investors With Losses Exceeding $200K to Actively Participate

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will be participating in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference. Presentation Detail

BELLUS Health to Participate in the 2021 RBC Capital Markets Global Healthcare Conference

Bellus (BLU) delivered earnings and revenue surprises of -33.33% and -60.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

News for Bellus Health Inc Stock (BLU)